Important note: human safe dosing has not been established for any of these compounds
In 2021, semaglutides weight-loss brand Wegovy (weekly injectable) was approved for obesity, followed by tirzepatide (Mounjaro) for diabetes (2022) and Zepbound (tirzepatide for obesity) in late 2023
This medication is not suitable for people with glaucoma, hyperthyroidism, or a history of stroke, substance use disorder, or some types of psychiatric illness
Adonis Saremi builds a complete framework individualized injection schedule, nutritional strategy, activity guidance, and behavioral coaching designed around your health profile and your life
Schedule a free call with one of our experts today, and let us help you discover the best Medicare plan options in your area
Debe combinarse con una dieta adecuada y ejercicio